A Simple Proton-Driven Allosteric Aptamer Nanorobot for Receptor Tyrosine Kinase Degradation and Behavior Modulation in Cancer Cells
Source abstract
Abstract
Abstract The aptamer-based strategy for selective protein degradation demonstrates broad application prospects in the field of biomedicine, particularly holding significant therapeutic potential for tumors and other protein dysregulation-related diseases. However, it faces substantial challenges due to on-target off-tumor effects arising from nonspecific expression of target proteins. To address this issue efficiently, we report here a pH-responsive allosteric DNA nanorobot (named A/I) that enhances the precision of aptamer-mediated target protein degradation through tumor microenvironment-specific activation. The allosteric nanorobot is comprised of two modules: the recognition module (A-strand) and the response module (I-strand). To be specific, the A-strand integrates both target recognition and degradation-inducing capabilities, while the I-strand blocks the recognition sites of the A-strand through complementary base pairing and confers pH sensitivity. Under physiological pH conditions, the A/I nanorobot exists stably in the form of a double-stranded structure. When the acidic tumor microenvironment is encountered, the pH-triggered conformational change of the I-strand induces the duplex disassembly, releasing the A-strand, which can specifically bind to the target protein and subsequently induce its degradation. Our findings demonstrate that the activatable allosteric nanorobot achieves targeted protein degradation, significantly inhibiting the proliferative and migratory abilities of tumor cells. In general, the activatable allosteric nanorobot has innovatively overcome the bottleneck of insufficient selectivity in traditional aptamer-based protein degradation strategies, providing a molecular tool for precision tumor therapy technologies. In addition, the allosteric nanorobot features a simple design and enables specific degradation of diverse target proteins by flexible replacement of the recognition module, demonstrating significant potential for constructing a universal protein precise degradation platform.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Phagocytosis and Immune Regulation · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Hunan University, Key Laboratory for Bio-Nanotechnology and Molecule Engineering of Hunan Province , , ,
Funding
National Natural Science Foundation of China
References (53)
Show source-provided references
1. The RTK Interactome: Overview and Perspective on RTK Heterointeractions10.1021/acs.chemrev.8b00467 ↗
2. A Transformable DNA Nano-Windmill for the Activation and Regulation of the Heterodimerization Receptors across RTK Families10.1016/j.cclet.2025.111049 ↗
3. Mechanisms of Receptor Tyrosine Kinase Activation in Cancer10.1186/s12943-018-0782-4 ↗
4. Nongenetic Engineering Strategies for Regulating Receptor Oligomerization in Living Cells10.1039/C9CS00473D ↗
5. Met, Metastasis, Motility and More10.1038/nrm1261 ↗
6. Proteostasis in Cardiac health and Disease10.1038/nrcardio.2017.89 ↗
7. Receptor Tyrosine Kinases (RTKs) in Breast Cancer: Signaling, Therapeutic Implications and Challenges10.1186/s12943-018-0797-x ↗
8. Role of Receptor Tyrosine Kinases Mediated Signal Transduction Pathways in Tumor Growth and Angiogenesis─New Insight and Futuristic Vision10.1016/j.ijbiomac.2021.03.075 ↗
9. Therapeutic Advances of Targeting Receptor Tyrosine Kinases in Cancer10.1038/s41392-024-01899-w ↗
10. ALK in Cancer: from Function to Therapeutic Targeting10.1038/s41568-025-00797-9 ↗
11. The Role of HGF/c-MET Signaling Pathway in Lymphoma10.1186/s13045-016-0366-y ↗
12. A Novel c-Met/TRK Inhibitor 1D228 Efficiently Inhibits Tumor Growth by Targeting Angiogenesis and Tumor Cell Proliferation10.1038/s41419-023-06246-5 ↗
13. Selective Inhibition of Cancer Cell Migration Using a pH-Responsive Nucleobase-Modified DNA Aptamer10.1039/D4SC04424J ↗
14. Molecularly Engineered siRNA Conjugates for Tumor-Targeted RNAi Therapy10.1016/j.jconrel.2022.09.040 ↗
15. Lactate-Responsive Gene Editing to Synergistically Enhance Macrophage-Mediated Cancer Immunotherapy10.1002/smll.202301519 ↗
16. A Smart mRNA-Initiated Theranostic Multi-shRNA Nanofactory for Precise and Efficient Cancer Gene Therapy10.1002/adhm.202404159 ↗
17. Dual Strategies Based on Golgi Apparatus/Endoplasmic Reticulum Targeting and Anchoring for High-Efficiency siRNA Delivery and Tumor RNAi Therapy10.1021/acsnano.4c14778 ↗
18. Engineering siRNA Therapeutics: Challenges and Strategies10.1186/s12951-023-02147-z ↗
19. mRNA-Activated Multifunctional DNAzyme Nanotweezer for Intracellular mRNA Sensing and Gene Therapy10.1021/acsami.0c21601 ↗
20. Nucleic Acid-Based Therapy for Brain Cancer: Challenges and Strategies10.1016/j.jconrel.2022.08.014 ↗
21. Targeting PI3K Family with Small-Molecule Inhibitors in Cancer Therapy: Current Clinical Status and Future Directions10.1186/s12943-024-02072-1 ↗
22. CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer10.1002/advs.202400666 ↗
23. Protein-Protein Interactions: Developing Small-Molecule Inhibitors/Stabilizers through Covalent Strategies10.1016/j.tips.2023.04.007 ↗
24. Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors10.3390/molecules28083615 ↗
25. Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges10.3390/molecules27175537 ↗
26. Novel Small Molecule Inhibitors Targeting Renal Cell Carcinoma: Status, Challenges, Future Directions10.1016/j.ejmech.2024.116158 ↗
27. Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials10.3390/cancers16173021 ↗
28. pH-Responsive Polypropylene Sulfide Magnetic Nanocarrier-Mediated Chemo-Hyperthermia Kills Breast Cancer Stem Cells by Long-Term Reversal of Multidrug Resistance and Chemotherapy Resensitization10.1021/acsami.3c12303 ↗
29. Chemically Engineered Antibodies for Autophagy-Based Receptor Degradation10.1038/s41589-024-01803-1 ↗
30. Delivering on the Promise of Protein Degraders10.1038/s41573-023-00652-2 ↗
31. Multivalent RGD Peptide-Mediated Nanochimera for Lysosomal Degradation of PDL1 Protein10.1021/acs.nanolett.5c00341 ↗
32. Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation10.1021/jacs.1c08521 ↗
33. Modular Cytokine Receptor-Targeting Chimeras for Targeted Degradation of Cell Surface and Extracellular Proteins10.1038/s41587-022-01456-2 ↗
34. Opportunities and Challenges of Protein-Based Targeted Protein Degradation10.1039/D3SC02361C ↗
35. In Vitro Selection of RNA Molecules that Bind Specific Ligands10.1038/346818a0 ↗
36. Aptamer Generated by Cell-SELEX for Specific Targeting of Human Glioma Cells10.1021/acsami.0c11878 ↗
37. Aptamer-Based Targeted Therapy10.1016/j.addr.2018.08.005 ↗
38. Modulating Aptamer Specificity with pH-Responsive DNA Bonds10.1021/jacs.8b08047 ↗
39. Aptamer-Based Targeted Protein Degradation10.1021/acsnano.2c10379 ↗
40. Aptamer Inhibits Tumor Growth by Leveraging Cellular Proteasomal Degradation System to Degrade c-Met in Mice10.1002/anie.202208451 ↗
41. Development of Integrin-Facilitated Bispecific Aptamer Chimeras for Membrane Protein Degradation10.1021/jacs.4c04794 ↗
42. Targeting c-MET in Gastrointestinal Tumours: Rationale, Opportunities and Challenges10.1038/nrclinonc.2017.40 ↗
43. HGF/MET Signaling in Malignant Brain Tumors10.3390/ijms21207546 ↗
44. An Acidic-Microenvironment-Driven DNA Nanomachine Enables Specific ATP Imaging in the Extracellular Milieu of Tumor10.1002/adma.201901885 ↗
45. Acidity Generated by the Tumor Microenvironment Drives Local Invasion10.1158/0008-5472.CAN-12-2796 ↗
46. Design of Tumor Microenvironment-Responsive Drug-Drug Micelle for Cancer Radiochemotherapy10.1021/acsami.8b11159 ↗
47. DNA Nanotriangle-Scaffolded Activatable Aptamer Probe with Ultralow Background and Robust Stability for Cancer Theranostics10.7150/thno.24683 ↗
48. Acidic Extracellular pH-Activated Allosteric DNA Nanodevice for Fluorescence Imaging of APE1 Activity in Tumor Cells10.1021/acs.analchem.4c03934 ↗
49. Engineering a Facile Aptamer “Molecule-Doctor” with Hairpin-Contained I-Motif Enables Accurate Imaging and Killing of Cancer Cells10.1021/acs.analchem.1c03580 ↗
50. Structural basis of the activation of c-MET Receptor10.1038/s41467-021-24367-3 ↗
51. Rational Design of Highly Responsive pH Sensors Based on DNA i-Motif10.1021/ja501859w ↗
52. Glutathione-Responsive Nano-Vehicles as a Promising Platform for Targeted Intracellular Drug and Gene Delivery10.1016/j.jconrel.2011.01.030 ↗
53. VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex10.1016/j.ccr.2012.05.037 ↗